These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 26618920)
1. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases. DuPont HL Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920 [TBL] [Abstract][Full Text] [Related]
2. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Pimentel M Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924 [TBL] [Abstract][Full Text] [Related]
3. Use of rifaximin in gastrointestinal and liver diseases. Shayto RH; Abou Mrad R; Sharara AI World J Gastroenterol; 2016 Aug; 22(29):6638-51. PubMed ID: 27547007 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases. DuPont HL Mayo Clin Proc; 2015 Aug; 90(8):1116-24. PubMed ID: 26162610 [TBL] [Abstract][Full Text] [Related]
6. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541 [TBL] [Abstract][Full Text] [Related]
7. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Bajaj JS Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922 [TBL] [Abstract][Full Text] [Related]
8. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. Sartor RB Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():27-36. PubMed ID: 26618923 [TBL] [Abstract][Full Text] [Related]
9. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. Laterza L; Ianiro G; Scoleri I; Landi R; Bruno G; Scaldaferri F; Gaetani E; Campanale M; Gasbarrini A Expert Opin Pharmacother; 2015 Mar; 16(4):607-15. PubMed ID: 25641072 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome. Bruzzese E; Pesce M; Sarnelli G; Guarino A Expert Opin Drug Metab Toxicol; 2018 Jul; 14(7):753-760. PubMed ID: 29897844 [TBL] [Abstract][Full Text] [Related]
12. [Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders]. Gasztonyi B; Hunyady B Orv Hetil; 2004 Oct; 145(43):2177-81. PubMed ID: 15575494 [TBL] [Abstract][Full Text] [Related]
13. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome. Kane JS; Ford AC Expert Rev Gastroenterol Hepatol; 2016; 10(4):431-42. PubMed ID: 26753693 [TBL] [Abstract][Full Text] [Related]
14. Review article: the antimicrobial effects of rifaximin on the gut microbiota. DuPont HL Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():3-10. PubMed ID: 26618921 [TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of the antibacterial rifaximin in the treatment of travellers' diarrhoea. Ericsson CD Drug Saf; 2006; 29(3):201-7. PubMed ID: 16524320 [TBL] [Abstract][Full Text] [Related]
16. Understanding the Molecular Mechanisms of Rifaximin in the Treatment of Gastrointestinal Disorders--A Focus on the Modulation of Host Tissue Function. Hirota SA Mini Rev Med Chem; 2015; 16(3):206-17. PubMed ID: 26202186 [TBL] [Abstract][Full Text] [Related]
17. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. Bajaj JS; Barbara G; DuPont HL; Mearin F; Gasbarrini A; Tack J Dig Liver Dis; 2018 Aug; 50(8):741-749. PubMed ID: 29807873 [TBL] [Abstract][Full Text] [Related]
18. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome. Li Y; Hong G; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X Pharmacol Res; 2020 Sep; 159():104936. PubMed ID: 32470562 [TBL] [Abstract][Full Text] [Related]
19. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron? Cash BD; Lacy BE; Rao T; Earnest DL Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529 [TBL] [Abstract][Full Text] [Related]
20. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. Ponziani FR; Gerardi V; Pecere S; D'Aversa F; Lopetuso L; Zocco MA; Pompili M; Gasbarrini A World J Gastroenterol; 2015 Nov; 21(43):12322-33. PubMed ID: 26604640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]